

## Viibryd® (vilazodone) – First-time generic

- On June 4, 2022, <u>Alembic</u>, <u>Accord</u> and <u>Teva</u> launched AB-rated generic versions of AbbVie's <u>Viibryd</u> (vilazodone) tablets.
  - In addition, Apotex launched an authorized brand alternative of Viibryd on the same day
  - <u>InvaGen/Cipla</u> received FDA approval of an AB-rated generic version of Viibryd on April 7, 2021. Launch plans are pending.
- Viibryd is approved for the treatment of major depressive disorder in adults.
- Viibryd carries a boxed warning for suicidal thoughts and behaviors.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.